The EU’s AI Act will reshape how pharma markets, personalises, and measures. This panel explore pharma frameworks, and how to stay compliant without holding back innovation.
Outcome: Leave a strong understanding of how AI solutions may violate the EU AI Act. Critical for those tasked with rolling out global initiatives in EU markets.
